Vildagliptin-induced bullous pemphigoid (retracted)

  • Santiago Campbell-Silva Clínica Mediláser (Florencia, Colombia)
  • Carlos Hernán Calderón Franco Magister en epidemiologia
  • Hailyn Andrea Marín-Castro Clínica Mediláser (Florencia, Colombia)
  • Cesia Victoria Beltrán-Jaramillo Clínica Mediláser (Florencia, Colombia)
  • Diego Julián Alvis-Peña Hospital Universitario Hernando Moncaleano Perdomo (Neiva, Colombia)
DOI: https://doi.org/10.36104/amc.2021.1942

Abstract

Retracted on 30th June 2021

The prevalence of type 2 diabetes continues to increase steadily as more people live longer, and dipeptidyl peptidase-4 inhibitors, oral medications with very low risk of hypoglycemia and neutral with respect to weight, become a therapeutic option for this group of older people. However, dipeptidyl peptidase-4 inhibitors have been associated with severe skin reactions including bullous pemphigoid, and due to the morbidity and mortality associated with this condition, it is necessary to sensitize health professionals to know this link and be alert to any adverse skin reaction of these medications in at risk populations.

We present two cases of bullous pemphigoid associated with vildagliptin.

Metrics

Metrics Loading ...
Published
2020-07-22
How to Cite
Campbell-Silva, S., Calderón Franco, C. H., Marín-Castro, H. A., Beltrán-Jaramillo, C. V., & Alvis-Peña, D. J. (2020). Vildagliptin-induced bullous pemphigoid (retracted). Acta Medica Colombiana, 46(2). https://doi.org/10.36104/amc.2021.1942
Issue
Vol. 46 No. 2 (2021): ACTA MEDICA COLOMBIANA-DIGITAL
Section
Case Reports

Acta Medica Colombiana uses the CC-BY 4.0 license. Authors retain all rights over their work.

Most read articles by the same author(s)